Quantinno Capital Management LP Purchases 2,228 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Quantinno Capital Management LP lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,202 shares of the medical research company's stock after purchasing an additional 2,228 shares during the quarter. Quantinno Capital Management LP's holdings in Thermo Fisher Scientific were worth $33,920,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Mufg Securities Americas Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at $2,938,000. MainStreet Investment Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $233,000. Malaga Cove Capital LLC lifted its holdings in Thermo Fisher Scientific by 56.4% during the 4th quarter. Malaga Cove Capital LLC now owns 1,722 shares of the medical research company's stock valued at $896,000 after purchasing an additional 621 shares during the last quarter. Nia Impact Advisors LLC grew its stake in Thermo Fisher Scientific by 12.1% during the fourth quarter. Nia Impact Advisors LLC now owns 10,184 shares of the medical research company's stock worth $5,298,000 after buying an additional 1,100 shares during the last quarter. Finally, Nomura Holdings Inc. increased its holdings in shares of Thermo Fisher Scientific by 179.1% during the fourth quarter. Nomura Holdings Inc. now owns 15,427 shares of the medical research company's stock worth $8,026,000 after buying an additional 9,899 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.9%

Shares of Thermo Fisher Scientific stock opened at $428.88 on Wednesday. The company has a market capitalization of $161.90 billion, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business has a 50-day moving average of $460.85 and a two-hundred day moving average of $513.11. Thermo Fisher Scientific Inc. has a 1 year low of $401.75 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the firm posted $5.11 earnings per share. The business's revenue was up .2% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock valued at $7,305,942 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Royal Bank of Canada decreased their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. StockNews.com downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Scotiabank cut their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.